<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25936344</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1791-3004</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Molecular medicine reports</Title><ISOAbbreviation>Mol Med Rep</ISOAbbreviation></Journal><ArticleTitle>Protective effect of enterovirus&#x2011;71 (EV71) virus&#x2011;like particle vaccine against lethal EV71 infection in a neonatal mouse model.</ArticleTitle><Pagination><StartPage>2473</StartPage><EndPage>2480</EndPage><MedlinePgn>2473-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3892/mmr.2015.3680</ELocationID><Abstract><AbstractText>Enterovirus-71 (EV71) is a viral pathogen that causes severe cases of hand, foot and mouth disease (HFMD) among young children, with significant mortality. Effective vaccines against HFMD are urgently required. Several EV71 virus-like particle (VLP) vaccine candidates were found to be protective in the neonatal mouse EV71 challenge model. However, to what extent the VLP vaccine protects susceptible organs against EV71 infection in vivo has remained elusive. In the present study, the comprehensive immunogenicity of a potential EV71 vaccine candidate based on VLPs was evaluated in a neonatal mouse model. Despite lower levels of neutralizing antibodies to EV71 in the sera of VLP-immunized mice compared with those in mice vaccinated with inactivated EV71, the VLP-based vaccine was shown to be able to induce immunoglobulin (Ig)G and IgA memory-associated cellular immune responses to EV71. Of note, the EV71 VLP vaccine candidate was capable of inhibiting viral proliferation in cardiac muscle, skeletal muscle, lung and intestine of immunized mice and provided effective protection against the pathological damage caused by viral attack. In particular, the VLP vaccine was able to inhibit the transportation of EV71 from the central nervous system to the muscle tissue and greatly protected muscle tissue from infection, along with recovery from the viral infection. This led to nearly 100% immunoprotective efficacy, enabling neonatal mice delivered by VLP-immunized female adult mice to survive and grow with good health. The present study provided valuable additional knowledge of the specific protective efficacy of the EV71 VLP vaccine in vivo, which also indicated that it is a promising potential candidate for being developed into an EV71 vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Viral Hepatitis, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 102206, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Fengfeng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory Animal Center, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Zheng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Viral Hepatitis, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 102206, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Viral Hepatitis, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 102206, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Viral Hepatitis, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 102206, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Ruiguang</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Viral Hepatitis, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 102206, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Qingling</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Viral Hepatitis, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 102206, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Zhiyuan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Viral Hepatitis, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 102206, P.R. China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Shengli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Viral Hepatitis, National Institute for Viral Disease Control and Prevention, China Center for Disease Control and Prevention, Beijing 102206, P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Mol Med Rep</MedlineTA><NlmUniqueID>101475259</NlmUniqueID><ISSNLinking>1791-2997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25936344</ArticleId><ArticleId IdType="pmc">PMC4464482</ArticleId><ArticleId IdType="doi">10.3892/mmr.2015.3680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9:78&#x2013;85. doi: 10.3201/eid1301.020112.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1301.020112</ArticleId><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev. 2002;26:91&#x2013;107. doi: 10.1111/j.1574-6976.2002.tb00601.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown BA, Pallansch MA. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 1995;39:195&#x2013;205. doi: 10.1016/0168-1702(95)00087-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, et al. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine. 2011;29:4362&#x2013;4372. doi: 10.1016/j.vaccine.2011.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.010</ArticleId><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J. Enterovirus 71 infection: A new threat to global public health? Lancet Neurol. 2008;7:868&#x2013;869. doi: 10.1016/S1474-4422(08)70207-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70207-2</ArticleId><ArticleId IdType="pmc">PMC7128195</ArticleId><ArticleId IdType="pubmed">18848307</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, Yu CK, Su IJ, Liu CC. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: Roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis. 2003;188:564&#x2013;570. doi: 10.1086/376998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/376998</ArticleId><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, Cho H, McMinn P. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: Comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis. 2003;9:461&#x2013;468. doi: 10.3201/eid0904.020395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0904.020395</ArticleId><ArticleId IdType="pmc">PMC2957976</ArticleId><ArticleId IdType="pubmed">12702227</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: Detection and molecular epidemiology of enterovirus 71. Microbiol Immunol. 2002;46:621&#x2013;627. doi: 10.1111/j.1348-0421.2002.tb02743.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2002.tb02743.x</ArticleId><ArticleId IdType="pubmed">12437029</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, He ML. The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol. 2011;37:313&#x2013;327. doi: 10.3109/1040841X.2011.580723.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1040841X.2011.580723</ArticleId><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M. Production of EV71 vaccine candidates. Hum Vaccin Immunother. 2012;8:1775&#x2013;1783. doi: 10.4161/hv.21739.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30:1305&#x2013;1312. doi: 10.1016/j.vaccine.2011.12.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol. 2003;11:438&#x2013;444. doi: 10.1016/S0966-842X(03)00208-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0966-842X(03)00208-7</ArticleId><ArticleId IdType="pubmed">13678860</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, Chiang YP, Chiang BL, Lee CY, Huang LM. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res. 2006;60:466&#x2013;471. doi: 10.1203/01.pdr.0000238247.86041.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000238247.86041.19</ArticleId><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8:e57601. doi: 10.1371/journal.pone.0057601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0057601</ArticleId><ArticleId IdType="pmc">PMC3579802</ArticleId><ArticleId IdType="pubmed">23451250</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Chang IS, Chen WJ, Huang YC, Chen GW, Shih SR, Juang JL, Shih HM, Hsiung CA, Lin TY, et al. HLA-A33 is associated with susceptibility to enterovirus 71 infection. Pediatrics. 2008;122:1271&#x2013;1276. doi: 10.1542/peds.2007-3735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2007-3735</ArticleId><ArticleId IdType="pubmed">19047245</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Foo DG, Trasti SL, Tan EL, Alonso S. Sustained high levels of interleukin-6 contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol. 2011;85:3067&#x2013;3076. doi: 10.1128/JVI.01779-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01779-10</ArticleId><ArticleId IdType="pmc">PMC3067852</ArticleId><ArticleId IdType="pubmed">21228224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cui W, Liu L, Wang J, Zhao H, Liao Y, Na R, Dong C, Wang L, Xie Z, et al. Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest. 2011;91:1337&#x2013;1350. doi: 10.1038/labinvest.2011.82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.2011.82</ArticleId><ArticleId IdType="pubmed">21555996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Devi S. Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease. J Virol. 2010;84:661&#x2013;665. doi: 10.1128/JVI.00999-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00999-09</ArticleId><ArticleId IdType="pmc">PMC2798416</ArticleId><ArticleId IdType="pubmed">19864378</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiung GD. Virus assay, neutralization test and antiviral assay. In: Hsiung GD, Fong CKY, Landry ML, editors. Hsiung&#x2019;s Diagnostic Virology. 4th ed. Yale University Press; New Haven: 1994. pp. 46&#x2013;55.</Citation></Reference><Reference><Citation>Cao L, Yi Y, Song JD, Tian MM, Tian RG, Meng QL, Qiu F, Jia ZY, Bi SL. The assemblage, purification and characterization of EV71 VLPs expressed in baculovirus. Bing Du Xue Bao. 2012;28:201&#x2013;206. In Chinese.</Citation><ArticleIdList><ArticleId IdType="pubmed">22764520</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia CS, Liu JN, Li WB, Ma CM, Lin SZ, et al. The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J. 2010;7:47. doi: 10.1186/1743-422X-7-47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-7-47</ArticleId><ArticleId IdType="pmc">PMC2839975</ArticleId><ArticleId IdType="pubmed">20170551</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T, Kolpe AB, Kiener TK, Chow VT, Kwang J. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS One. 2011;6:e21757. doi: 10.1371/journal.pone.0021757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021757</ArticleId><ArticleId IdType="pmc">PMC3128602</ArticleId><ArticleId IdType="pubmed">21747954</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta C, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012;19:424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen ZS, Xu YL, Zou XT, Xu ZR. Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs. 2011;9:1038&#x2013;1055. doi: 10.3390/md9061038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/md9061038</ArticleId><ArticleId IdType="pmc">PMC3131560</ArticleId><ArticleId IdType="pubmed">21747747</ArticleId></ArticleIdList></Reference><Reference><Citation>Emeny RT, Wheeler CM, Jansen KU, Hunt WC, Fu TM, Smith JF, MacMullen S, Esser MT, Paliard X. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol. 2002;76:7832&#x2013;7842. doi: 10.1128/JVI.76.15.7832-7842.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.15.7832-7842.2002</ArticleId><ArticleId IdType="pmc">PMC136358</ArticleId><ArticleId IdType="pubmed">12097595</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007;81:3514&#x2013;3524. doi: 10.1128/JVI.02052-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02052-06</ArticleId><ArticleId IdType="pmc">PMC1866067</ArticleId><ArticleId IdType="pubmed">17251294</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhao H, Zhang Y, Wang J, Che Y, Dong C, Zhang X, Na R, Shi H, Jiang L, et al. Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology. 2011;412:91&#x2013;100. doi: 10.1016/j.virol.2010.12.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.12.058</ArticleId><ArticleId IdType="pubmed">21262515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Duo J, Liu J, Ma C, Zhang L, Wei Q, Qin C. A mouse muscle-adapted enterovirus 71 strain with increased virulence in mice. Microbes Infect. 2011;13:862&#x2013;870. doi: 10.1016/j.micinf.2011.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2011.04.004</ArticleId><ArticleId IdType="pubmed">21612764</ArticleId></ArticleIdList></Reference><Reference><Citation>Duo J, Wang W, Tong W, Cong Z, Jiang H, Xu W, et al. Experimental Studies on ICR Mice with EV71 Infection. Chin J Comp Med. 2009;19:41&#x2013;46.</Citation></Reference><Reference><Citation>Xiu JH, Zhu H, Xu YF, Liu JN, Xia XZ, Zhang LF. Necrotizing myositis causes restrictive hypoventilation in a mouse model for human enterovirus 71 infection. Virol J. 2013;10:215. doi: 10.1186/1743-422X-10-215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-215</ArticleId><ArticleId IdType="pmc">PMC3710232</ArticleId><ArticleId IdType="pubmed">23809248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>